ConductScience.org, home

Paper41379320

Efficacy and safety of lorundrostat in uncontrolled hypertension: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials.

Alam U and 10 others. Naunyn Schmiedebergs Arch Pharmacol, 2026. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Efficacy and safety of lorundrostat in uncontrolled hypertension: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials. Papers, record 41379320. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41379320

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy and safety of lorundrostat in uncontrolled hypertension: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials.
PubMed
Journal
Naunyn Schmiedebergs Arch Pharmacol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Systematic Review, Meta-Analysis
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2026-11-03
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Alam UUmama
2Rath SShreehttps://orcid.org/0009-0000-4273-0827
3Javed JJaveria
4Khan ASAkif Shahid
5Moiz AAbdul
6Ansab MMuhammad
7Hameed AAlishba
8Bacha ZZaryab
9Afridi ZAKZarar Ahmad Khan
10Khan KKhushal
11Ahmed RRaheel

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
HypertensionMajor topic
Antihypertensive AgentsMajor topic
Blood PressureMajor topic
Humans
Randomized Controlled Trials as Topic
Treatment Outcome
Cytochrome P-450 CYP11B2

Source PubMed

Download CSV of topics

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139656736Aldosterone Synthase Inhibitors: A Revival for Treatment of Renal and Cardiovascular Diseases.J Clin Endocrinol Metab2025https://conductscience.org/library/papers/39656736PubMed
29310563Bias in meta-analysis detected by a simple, graphical test.BMJ1997https://conductscience.org/library/papers/9310563PubMed
321599961Use, tolerability and compliance of spironolactone in the treatment of heart failure.BMC Clin Pharmacol2011https://conductscience.org/library/papers/21599961PubMed
412423980Selected major risk factors and global and regional burden of disease.Lancet2002https://conductscience.org/library/papers/12423980PubMed
540587141Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial.JAMA2025https://conductscience.org/library/papers/40587141PubMed
629133354
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Hypertension2018https://conductscience.org/library/papers/29133354PubMed
727502908Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries.Circulation2016https://conductscience.org/library/papers/27502908PubMed
839270739Global burden of cardiovascular diseases: projections from 2025 to 2050.Eur J Prev Cardiol2025https://conductscience.org/library/papers/39270739PubMed
99308599Epidemiology and prevention of hypertension.Med Clin North Am1997https://conductscience.org/library/papers/9308599PubMed
1034450083Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.Lancet2021https://conductscience.org/library/papers/34450083PubMed
1139077590β-Blockers and Erectile Dysfunction in Heart Failure. Between Myth and Reality.Rev Cardiovasc Med2022https://conductscience.org/library/papers/39077590PubMed
1212668699Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.N Engl J Med2003https://conductscience.org/library/papers/12668699PubMed
1340115559Prevalence and associated risk factors of hypertension in rural and urban areas of Punjab: A cross-sectional study.J Family Med Prim Care2025https://conductscience.org/library/papers/40115559PubMed
1437690061Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.JAMA2023https://conductscience.org/library/papers/37690061PubMed
1535390421Determining risk factors for triple whammy acute kidney injury.Math Biosci2022https://conductscience.org/library/papers/35390421PubMed
1633782057The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.BMJ2021https://conductscience.org/library/papers/33782057PubMed
1731529687Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis.Arthritis Care Res (Hoboken)2020https://conductscience.org/library/papers/31529687PubMed
1826364544
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.
Lancet2015https://conductscience.org/library/papers/26364544PubMed
1937309038The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.Nephrol Dial Transplant2023https://conductscience.org/library/papers/37309038PubMed
2026414968Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.Lancet2015https://conductscience.org/library/papers/26414968PubMed

See all 34 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42489850When Methods Matter: An Umbrella Review of Lorundrostat and the Impact of Analytical Decisions on Reported Blood Pressure and Safety Outcomes.Am J Cardiovasc Drugs2026https://conductscience.org/library/papers/42489850PubMed
41714376
The impact of acute normovolemic hemodilution on blood transfusions in cardiac surgery: a GRADE-assessed systematic review and meta-analysis of 30 randomized controlled trials with trial sequential analysis.
Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/41714376PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CYP11B21585PubTator's text mininghttps://conductscience.org/library/genes/1585

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41379320

GET https://conductscience.org/api/papers/v1/41379320/references?page=2